The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback